BRIDGEBIO PHARMA INC (BBIO)
US10806X1028 - Common Stock
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -446.29M | -653.25M | -484.65M | -586.45M | -505.49M | |||
| Depreciation Amortization | 6.29M | 6.49M | 6.77M | 5.84M | N/A | |||
| Change In Working Capital | 41.07M | 5.06M | 34.34M | -1.06M | 14.93M | |||
| Interest Paid | 88.51M | 61.11M | 54.44M | 29.77M | 15.32M | |||
| Other non cash items | -51.31M | 113.98M | 24.05M | 83.74M | 90.84M | |||
| OPERATING CASH FLOW | -450.22M | -527.72M | -419.49M | -497.93M | -399.71M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -6.11M | -1.31M | -6.32M | -13.25M | -7.52M | |||
| Other Investing Activity | 70.06M | 55.34M | 459.47M | -187.58M | -45.48M | |||
| INVESTING CASH FLOW | 63.95M | 54.03M | 453.15M | -200.83M | -52.99M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -23.42M | 0.00 | -20.49M | 1.08B | 550.00M | |||
| Stock Issued/Repurchased | 304.40M | 459.22M | 8.08M | -179.54M | -60.87M | |||
| Other Financing Activity | -10.97M | -7.68M | -720.00K | -163.70M | -41.94M | |||
| FINANCING CASH FLOW | 270.00M | 451.54M | -13.13M | 736.45M | 447.19M | |||
| CHANGE IN CASH | -116.27M | -22.15M | 20.53M | 37.69M | -5.51M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -450.22M | -527.72M | -419.49M | -497.93M | -399.71M | |||
| Capital Expenditure | -6.11M | -1.31M | -6.32M | -13.25M | -7.52M | |||
| FREE CASH FLOW | -456.33M | -529.03M | -425.81M | -511.18M | -407.23M | |||
All data in USD